Nov 30, 2023
Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney WINSTON-SALEM, N.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)  (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
Nov 14, 2023
WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023.
Jun 13, 2023
WINSTON-SALEM, N.C., June 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced its